Publications by authors named "Isabelle Moullet"
Article Synopsis
- - The study aimed to evaluate the effectiveness and safety of combining eribulin with bevacizumab as a first-line treatment for HER2-negative metastatic breast cancer, comparing it to previous regimens like paclitaxel.
- - In a clinical trial involving 61 women, the combination treatment resulted in a 32% non-progression rate at one year and a median progression-free survival of 8.3 months, indicating promising results.
- - Adverse effects were reported, with hypertension (39%) and neutropenia (26%) being the most common serious side effects, but overall, the treatment was considered to have an acceptable safety profile with low rates of severe neuropathy.
Benefits of physical activity are widely demonstrated for early stage cancers but few studies have focused on metastatic disease. The purpose of this study was to determine the impact of physical activity on survival in patients with metastatic breast cancer. We conducted a secondary analysis of the national, multicentric, non-randomized, prospective cohort SNPs to Risk of Metastasis (StoRM) study.
View Article and Find Full Text PDFOBJECTIVES. As vascular endothelial growth factor (VEGF) is expressed in ovarian cancer, we assessed the efficacy and safety of bevacizumab (a monoclonal antibody targeting VEGF) plus microtubule targeting agents for heavily pre-treated ovarian carcinoma patients. METHODS.
View Article and Find Full Text PDFObjectives: This study aimed to provide further clinical evidence for the efficacy and safety of epoetin beta once weekly across a wide range of cancer types.
Methods: This was a multicenter, open-label, prospective, single-arm study in patients with either a solid tumor or non-myeloid hematological malignancy, receiving or scheduled to receive further chemotherapy. Patients received epoetin beta 30,000 IU subcutaneously once weekly for 16 weeks.